Wolters E C, Riekkinen P, Lowenthal A, Van der Plaats J J, Zwart J M, Sennef C
Department of Neurology, Amsterdam Free University, The Netherlands.
Neurology. 1990 Jul;40(7):1099-101. doi: 10.1212/wnl.40.7.1099.
We carried out a double-blind study of a vasopressin-related peptide, DGAVP citrate (Org 5667), in 115 patients with mild dementia, probable Alzheimer's type (DAT). Neither clinical rating scales nor psychometric tests revealed any improvement over 84 days with once-daily intranasal treatment with 2 different doses of DGAVP. We conclude that vasopressin-like peptides are not satisfactory therapeutic agents in DAT.
我们对115例轻度痴呆（可能为阿尔茨海默病类型，即DAT）患者进行了一项关于血管加压素相关肽——枸橼酸去甘氨加压素（Org 5667）的双盲研究。无论是临床评定量表还是心理测量测试都显示，采用两种不同剂量的DGAVP每日一次经鼻给药治疗84天，均未发现有任何改善。我们得出结论，在DAT中，类血管加压素肽并非令人满意的治疗药物。
